Acellular dermal matrix is a biologically derived product, which is devoid of cells. The main components of acellular dermal matrix include collagen and elastic fibers. In the recent past, there is a remarkable growth in application of acellular dermal matrices in plastic surgery, cosmetic surgery, breast reconstruction, and wound healing. Acellular dermal matrices were initially used in the resurfacing of burn injuries, abdominal wall repair, tympanic membrane replacement, dural repairs, and gingival grafting.
The U.S. Acellular Dermal Matrices Market is estimated to be valued at US$ 2,057.3 million in 2020 and is expected to exhibit a CAGR of 10.6% during the forecast period (2020-2027).
Figure 1.U.S. Acellular Dermal Matrices Market Share (%) in Terms of Value, By Origin 2020
The increasing product launch and approval is expected to drive the market growth during the forecast period.
Key players operating in the U.S. acellular dermal matrices market are focusing on launch and approval of technologically advanced acellular dermal matrices in the market, which is expected to drive the market growth over the forecast period. For instance, In April 2018, Musculoskeletal Transplant Foundation Biologics (MTF Biologics), a non-government organization, launched FlexHD Pliable PRE acellular dermal matrix that is designed especially for breast reconstruction procedures.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2020: | US$ 2,057.3 Mn |
| Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: | 10.6% | 2027 Value Projection: | US$ 4,167.8 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, Marine Polymer Technologies, Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2 .U.S. Acellular Dermal Matrices Market Share (%), by Application, 2020
The rising number of surgeries are expected to drive expected to drive the market growth during the forecast period
Increased number of surgeries in the U.S. is expected to drive the growth of acellular dermal matrices market in the U.S. over the forecast period. For instance, according to the American Society of Plastic Surgeons 2019 report, around 265,209 liposuction surgeries were performed using acellular dermal matrices in 2019.
U.S. Acellular Dermal Matrices Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 166 million infected individuals worldwide as of May 24th 2021.
COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. The pandemic had a major impact on the U.S., Japan, China, as well as other major European countries. Due to the increasing prevalence of COVID-19, key players operating in the U.S. acellular dermal matrices market are focusing on research and development of novel products to support and combat the effect of COVID-19. COVID-19 pandemic has impacted the global economy and, in turn, the U.S. Acellular Dermal Matrices Market. Quarantines, traveling constraints, and social distancing measures are likely to lead to a steep decline in business and consumer spending until the end of the third quarter of 2020.
U.S. Acellular Dermal Matrices Market: Restraint
The major factors that hinder the growth of the U.S. acellular dermal matrices market include complications of acellular dermal matrices in breast surgery and plastic surgery and product recall
Key Players
Major players operating in the U.S. Acellular dermal matrices market are Integra LifeSciences Corporation*, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, Marine Polymer Technologies, Inc.
Acellular dermal matrices are generated by decellularization process, which leads to the removal of the cells and preserving of the extracellular matrix. The extracellular matrix ones implanted in the required area, serves as the scaffold for the donor cells. The donor cells help in the revascularization, which in turn generates a new tissue. The main components of acellular dermal matrix include collagen and elastic fibers. Acellular dermal matrices are mostly used in breast surgery and plastic surgery. Seroma, infection, mastectomy skin necrosis, and expander/implant loss are the most commonly reported complications of acellular dermal matrices with respect to breast surgery.
Market Dynamics
The key player in the market focusing on adopting inorganic growth strategies such as acquisition and collaboration expected to drive the growth of acellular dermal matrices market over the forecast period. For instance, In December 2020, Integra Lifesciences Corporation acquired ACell, Inc., a U.S.-based biotechnology company. The acquisition helped Integra to expand its portfolio of acellular dermal matrix. Furthermore, In December 2019, Smith & Nephew Plc. Acquired Osiris Therapeutics Inc., a regenerative medicine company that offers skin, bone graft, and articular cartilage substitutes. The
acquisition helped Smith & Nephew Plc. To expand its product portfolio of acellular dermal matrix. Moreover, In April 2019, Cook Biotech, a biotechnological subsidiary of Cook Group, entered into a sales collaboration with Progressive Medical Inc., a U.S.-based medical products sales and marketing company. As a result of this sales collaboration, sales representatives employed by Progressive Medical would manage and support sales for the Cook Biotech Biodesign Hernia Graft in the U.S.
Key features of the study:
Detailed Segmentation:
‘*’ marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients